Home・Akciju saraksts・Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Slēgts

SektorsVeselības aprūpe

1.14 -11.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.1400000000000001

Max

1.29

Galvenie mērījumi
By Trading Economics
Ienākumi	32M -8.3M
Pārdošana	-7.5M 37M
EPS	-0.12
Peļņas marža	-22.258
Darbinieki	485
EBITDA	33M -5.8M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+83.08% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-40M 441M
Iepriekšējā atvēršanas cena	12.77
Iepriekšējā slēgšanas cena	1.14

Ziņu noskaņojums

By Acuity

50%

156 / 340 Rangs Healthcare

Pacific Biosciences of California Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. aug. 23:01 UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

2026. g. 4. aug. 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

2026. g. 3. aug. 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

2026. g. 31. jūl. 19:46 UTC

News

Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

2026. g. 29. jūl. 16:06 UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

2026. g. 28. jūl. 16:12 UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

2026. g. 27. jūl. 19:06 UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

2026. g. 24. jūl. 22:31 UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

2026. g. 22. jūl. 18:01 UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

2026. g. 21. jūl. 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

2026. g. 20. jūl. 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Salīdzinājums

Cenas izmaiņa

Pacific Biosciences of California Inc Prognoze

Cenas mērķis

By TipRanks

83.08% augšup

Prognoze 12 mēnešiem

Vidējais 2.38 USD 83.08%

Augstākais 3 USD

Zemākais 1.5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Pacific Biosciences of California Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pacific Biosciences of California Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

156 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.